Latest news and press releases about Syndax Pharmaceuticals, Inc. (SNDX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML).
Price
| Price | $17.28 |
| Market Cap | $1.5B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 101.04 |
| EV / EBITDA | -14.93 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -372.94% |
| Return on Invested Capital | -32.10% |
| Return on Assets | -31.37% |
| Gross Margin | 97.47% |
| Operating Margin | -77.05% |
| Net Margin | -87.60% |
Related companies: AMLX · ATAI · CVAC · IMTX · INBX · NKTR · ORIC
Explore sector: Healthcare · Biotechnology
More sections of SNDX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks